Why Connected Compliance Is Critical to Commercial Success

Vikram Anand, President of Compliance Services at EVERSANA, recently sat down with Pharmaceutical Commerce for a series of interviews discussing how compliance infrastructure can impact commercialization success. 

Anand highlighted how many commercial delays stem from disconnected compliance processes and pharmacovigilance (PV) systems, rather than traditional operational challenges alone.  

Manufacturers can reduce regulatory friction, improve safety oversight, and better prepare for successful commercialization through more connected compliance strategies.  

Compliance Readiness: The Hidden Gatekeeper 

A key theme across the discussion in a series of multiple interviews is that commercialization delays are not always driven by visible manufacturing or supply chain issues. 

Gaps in safety reporting, fragmented systems, and unclear compliance ownership can create significant regulatory hurdles, delaying approvals and slowing product launches.  

Companies who address these challenges before submission can prevent avoidable friction during the review process.  

The Cost of Disconnected Pharmacovigilance 

Fragmented PV systems can create substantial operational inefficiencies.  

When safety databases, clinical operations, and reporting functions are disconnected, teams often rely on manual processes that slow case management, signal detection, and regulatory reporting. This results in:

• Delayed decision-making 
• Increased compliance risk 
• Slower launch timelines 

As pharmacovigilance requirements continue to grow in complexity, compliance processes must evolve too — but as one.  

The Future of Compliance is Connected and Intelligent 

The conversations also point to a future where PV is increasingly driven by automation, AI, and integrated data ecosystems. 

Manufacturers moving beyond isolated systems toward connected platforms are improving data visibility, accelerating safety monitoring, and supporting faster decision-making.  

Anand emphasizes the increasing importance of these investments as organizations prepare for evolving regulatory expectations and more complex therapies.  

Explore the Full Video Interview Series 

• Vikram Anand on the “Hidden Gatekeeper” Behind Commercial Delays | Pharmaceutical Commerce
• Vikram Anand on PV Infrastructure Gaps | Pharmaceutical Commerce
• Where Connected Pharmacovigilance Is Headed Next | Pharmaceutical Commerce

Learn more about EVERSANA’s integrated commercial compliance solutions 

Read the latest POV: You Cannot Commercialize What Is Not Compliant: Rethinking Launch Readiness to Prevent CRL Setbacks